Cargando…

Epidermal growth factor receptor mRNA expression: A potential molecular escape mechanism from regorafenib

Regorafenib has improved the survival of patients with refractory metastatic colorectal cancer (mCRC), yet the mechanisms of inherited or acquired resistance are not well understood. A total of 50 patients with refractory mCRC were enrolled. Circulating tumor cell (CTC) enumeration was carried out a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsusaka, Satoshi, Hanna, Diana L., Ning, Yan, Yang, Dongyun, Cao, Shu, Berger, Martin D., Miyamoto, Yuji, Suenaga, Mitsukuni, Dan, Shingo, Mashima, Tetsuo, Seimiya, Hiroyuki, Zhang, Wu, Lenz, Heinz‐Josef
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004533/ https://www.ncbi.nlm.nih.gov/pubmed/31821662 http://dx.doi.org/10.1111/cas.14273

Ejemplares similares

Serum VEGF-A and CCL5 levels as candidate biomarkers for efficacy and toxicity of regorafenib in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2016)

A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer
por: Miyamoto, Yuji, et al.
Publicado: (2020)

Impact of sex, age, and ethnicity/race on the survival of patients with rectal cancer in the United States from 1988 to 2012
por: Berger, Martin D., et al.
Publicado: (2016)

Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial
por: Suenaga, Mitsukuni, et al.
Publicado: (2020)

Factors Associated With Regorafenib Adherence With Metastatic Colorectal Cancer
por: Kawakami, Kazuyoshi, et al.
Publicado: (2019)

Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab
por: Osumi, Hiroki, et al.
Publicado: (2015)

Cetuximab could be more effective without prior bevacizumab treatment in metastatic colorectal cancer patients
por: Sato, Yasuyoshi, et al.
Publicado: (2015)

Comparison between three oxaliplatin-based regimens with bevacizumab in patients with metastatic colorectal cancer
por: Ohhara, Yoshihito, et al.
Publicado: (2015)

Regorafenib-Induced Hand–Foot Skin Reaction Is More Severe on the Feet Than on the Hands
por: Nonomiya, Yuma, et al.
Publicado: (2019)

In silico chemical screening identifies epidermal growth factor receptor as a therapeutic target of drug-tolerant CD44v9-positive gastric cancer cells
por: Mashima, Tetsuo, et al.
Publicado: (2019)

Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
por: Schirripa, Marta, et al.
Publicado: (2018)

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin- and irinotecan-based treatment in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2018)

Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Acquired drug resistance conferred by a KRAS gene mutation following the administration of cetuximab: a case report
por: Osumi, Hiroki, et al.
Publicado: (2013)

Strategic Insight into the Combination Therapies for Metastatic Colorectal Cancer
por: Kano, Yoshihito, et al.
Publicado: (2023)

Does anti-p53 antibody status predict for clinical outcomes in metastatic colorectal cancer patients treated with fluoropyrimidine, oxaliplatin, plus bevacizumab as first-line chemotherapy?
por: Osumi, Hiroki, et al.
Publicado: (2015)

Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01)
por: Suenaga, Mitsukuni, et al.
Publicado: (2015)

Polymorphisms within Immune Regulatory Pathways Predict Cetuximab Efficacy and Survival in Metastatic Colorectal Cancer Patients
por: Volz, Nico B., et al.
Publicado: (2020)

Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
por: Nishiya, Naoyuki, et al.
Publicado: (2021)

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors
por: Weekes, Colin, et al.
Publicado: (2019)

De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy
por: Mashima, T, et al.
Publicado: (2009)

Germline polymorphisms in genes involved in the Hippo pathway as recurrence biomarkers in stage II/III colon cancer
por: Sebio, Ana, et al.
Publicado: (2015)

Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)

ALDH1A3‐mTOR axis as a therapeutic target for anticancer drug‐tolerant persister cells in gastric cancer
por: Kawakami, Ryuhei, et al.
Publicado: (2020)

Comprehensive transcriptomic analysis of molecularly targeted drugs in cancer for target pathway evaluation
por: Mashima, Tetsuo, et al.
Publicado: (2015)

Comprehensive Genomic Profiling of Circulating Cell-Free DNA Distinguishes Focal MET Amplification from Aneuploidy in Diverse Advanced Cancers
por: Kumaki, Yuichi, et al.
Publicado: (2021)

Clinical Significance of Circulating Tumor Cell Induced Epithelial-Mesenchymal Transition in Patients with Metastatic Colorectal Cancer by Single-Cell RNA-Sequencing
por: Kozuka, Masahiro, et al.
Publicado: (2021)

mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer
por: Mashima, Tetsuo, et al.
Publicado: (2017)

Neutralization of the induced VEGF-A potentiates the therapeutic effect of an anti-VEGFR2 antibody on gastric cancer in vivo
por: Mashima, Tetsuo, et al.
Publicado: (2021)

Pharmacologic activity and pharmacokinetics of metabolites of regorafenib in preclinical models
por: Zopf, Dieter, et al.
Publicado: (2016)

Trends in colorectal cancer mortality in hispanics: a SEER analysis
por: Barzi, Afsaneh, et al.
Publicado: (2017)

Erythema multiforme induced by regorafenib
por: Matsunaga, Mototsugu, et al.
Publicado: (2017)

Interaction Between Sex and Organic Anion‐Transporting Polypeptide 1b2 on the Pharmacokinetics of Regorafenib and Its Metabolites Regorafenib‐N‐Oxide and Regorafenib‐Glucuronide in Mice
por: Fu, Qiang, et al.
Publicado: (2019)

Practical considerations in the use of regorafenib in metastatic colorectal cancer
por: Loupakis, Fotios, et al.
Publicado: (2020)

Incidence and risk of regorafenib-induced hepatotoxicity
por: Zhao, Bin, et al.
Publicado: (2017)

Experience with regorafenib in the treatment of hepatocellular carcinoma
por: Granito, Alessandro, et al.
Publicado: (2021)

Characterization of Glioblastoma Cells Response to Regorafenib
por: Mongiardi, Maria Patrizia, et al.
Publicado: (2022)

Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice
por: Wang, Wan, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_imuf3ocq8pgifvqljbb39fn4m7